Brokers Issue Forecasts for ORIC FY2025 Earnings

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Cantor Fitzgerald issued their FY2025 earnings estimates for ORIC Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn ($2.32) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($1.84) per share.

ORIC Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.01).

Several other equities research analysts also recently issued reports on ORIC. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Monday, January 13th. Wells Fargo & Company assumed coverage on shares of ORIC Pharmaceuticals in a research note on Thursday, October 31st. They issued an “overweight” rating and a $20.00 price objective on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $20.00 price target on shares of ORIC Pharmaceuticals in a research note on Monday, January 13th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $18.29.

ORIC Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ:ORIC opened at $9.87 on Thursday. The stock has a fifty day moving average of $8.97 and a 200-day moving average of $9.54. ORIC Pharmaceuticals has a one year low of $6.33 and a one year high of $16.65.

Institutional Trading of ORIC Pharmaceuticals

A number of large investors have recently made changes to their positions in ORIC. Creative Planning acquired a new stake in ORIC Pharmaceuticals during the 3rd quarter worth approximately $116,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of ORIC Pharmaceuticals in the third quarter valued at about $132,000. China Universal Asset Management Co. Ltd. boosted its position in shares of ORIC Pharmaceuticals by 71.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,568 shares of the company’s stock worth $139,000 after buying an additional 5,646 shares during the period. XTX Topco Ltd bought a new position in shares of ORIC Pharmaceuticals during the second quarter worth about $153,000. Finally, Profund Advisors LLC raised its position in ORIC Pharmaceuticals by 23.6% in the 2nd quarter. Profund Advisors LLC now owns 21,861 shares of the company’s stock valued at $155,000 after buying an additional 4,175 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

Insiders Place Their Bets

In other news, insider Pratik S. Multani sold 8,850 shares of ORIC Pharmaceuticals stock in a transaction on Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $73,278.00. Following the completion of the sale, the insider now directly owns 46,765 shares of the company’s stock, valued at approximately $387,214.20. This trade represents a 15.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jacob Chacko sold 24,660 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $204,184.80. Following the transaction, the chief executive officer now directly owns 778,648 shares in the company, valued at $6,447,205.44. This trade represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,361 shares of company stock valued at $350,749. 5.55% of the stock is currently owned by corporate insiders.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.